Evidence map›Paper›PMID 30947285›Full record

ArticlePloS one2019

Cyclophosphamide and the taste system: Effects of dose fractionation and amifostine on taste cell renewal.

Eugene R Delay, Sarah H Socia, Jessica L Girardin, Benjamin C Jewkes, John H King, Rona J Delay

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Developing and regenerating a sense of taste.Current topics in developmental biology · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Molecular and Neural Mechanism of Dysphagia Due to Cancer.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Eugene R DelayDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.ORCID 0000-0002-2405-1182
Sarah H SociaDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.
Jessica L GirardinDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.
Benjamin C JewkesDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.
John H KingDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.
Rona J DelayDepartment of Biology and Neuroscience Program, University of Vermont, Burlington, Vermont, United States of America.
University of Vermont · US

Funding

Taste and Cyclophosphamide in MiceR01DC012829 · NIDCD · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI DELAY, EUGENE R · 2013 to 2015
$570k
NIDCD NIH HHS R01 DC012829
6 · The paper itself

Abstract

Chemotherapy often causes side effects that include disturbances in taste functions. Cyclophosphamide (CYP) is a chemotherapy drug that, after a single dose, elevates murine taste thresholds at times related to drug-induced losses of taste sensory cells and disruptions of proliferating cells that renew taste sensory cells. Pretreatment with amifostine can protect the taste system from many of these effects. This study compared the effects of a single dose (75 mg/kg) of CYP with effects generated by fractionated dosing of CYP (5 doses of 15 mg/kg), a dosing approach often used during chemotherapy, on the taste system of mice using immunohistochemistry. Dose fractionation prolonged the suppressive effects of CYP on cell proliferation responsible for renewal of taste sensory cells. Fractionation also reduced the total number of cells and the proportion of Type II cells within taste buds. The post-injection time of these losses coincided with the life span of Type I and II taste cells combined with lack of replacement cells. Fractionated dosing also decreased Type III cells more than a single dose, but loss of these cells may be due to factors related to the general health and/or cell renewal of taste buds rather than the life span of Type III cells. In general, pretreatment with amifostine appeared to protect taste cell renewal and the population of cells within taste buds from the cytotoxic effects of CYP with few observable adverse effects due to repeated administration. These findings may have important implications for patients undergoing chemotherapy.

Indexed as

AmifostineAnimalsAntineoplastic AgentsCell CountCell ProliferationCyclophosphamideDose-Response Relationship, DrugHumansImmunohistochemistryMaleMiceMice, Inbred C57BLPhospholipase C betaProtective AgentsSynaptosomal-Associated Protein 25TasteAmifostineAntineoplastic AgentsCyclophosphamidePhospholipase C betaPlcb2 protein, mouseProtective AgentsSnap25 protein, mouseSynaptosomal-Associated Protein 25

Identifiers

PMID30947285
PMCPMC6448888
OpenAlexW2931157775

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.